BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling (Q44456291)

3 December 2017

BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling (English)

1 reference

3 December 2017

12

1 reference

3 December 2017

15

1 reference

3 December 2017

Berta Sanchez-Laorden

object named as

Berta Sanchez-Laorden

1

0 references

Caroline J Springer

object named as

Caroline Springer

14

0 references

Alfonso Zambon

object named as

Alfonso Zambon

6

0 references

author name string

Amaya Viros

2

1 reference

3 December 2017

Maria Romina Girotti

3

1 reference

3 December 2017

Malin Pedersen

4

1 reference

3 December 2017

Grazia Saturno

5

1 reference

3 December 2017

Dan Niculescu-Duvaz

7

1 reference

3 December 2017

Samra Turajlic

8

1 reference

3 December 2017

Andrew Hayes

9

1 reference

3 December 2017

Martin Gore

10

1 reference

3 December 2017

James Larkin

11

1 reference

3 December 2017

Martin Cook

13

1 reference

3 December 2017

25 March 2014

1 reference

3 December 2017

1 reference

3 December 2017

7

1 reference

3 December 2017

318

1 reference

3 December 2017

ra30

1 reference

Melanoma biology and new targeted therapy

3 December 2017

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004815

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004815

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004815

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004815

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004815

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004815

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004815

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004815

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004815

Role of matrix metalloproteinases in melanoma cell invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004815

IL-8-stimulated expression of urokinase-type plasminogen activator in human skin and human epidermal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004815

PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004815

Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004815

uPAR: a versatile signalling orchestrator

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004815

Urokinase plasminogen activator receptor: Prognostic biomarker for endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004815

uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004815

Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004815

Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004815

Rac activation and inactivation control plasticity of tumor cell movement

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004815

Prespecification and plasticity: shifting mechanisms of cell migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004815

Plasticity of cell migration: a multiscale tuning model

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004815

Rac mediates cytoskeletal rearrangements and increased cell motility induced by urokinase-type plasminogen activator receptor binding to vitronectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004815

Mitogen-activated and cyclin-dependent protein kinases selectively and differentially modulate transcriptional enhancement by the glucocorticoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004815

The multifactorial role of leptin in driving the breast cancer microenvironment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004815

Regulatory mechanisms controlling human hepatocyte nuclear factor 4alpha gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004815

Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004815

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004815

Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004815

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004815

Inducible expression of (V600E) Braf using tyrosinase-driven Cre recombinase results in embryonic lethality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004815

Improving melanoma classification by integrating genetic and morphologic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004815

Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004815

Proteases in cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004815

10.1126/SCISIGNAL.2004815

21 January 2018

Identifiers

DOI

1 reference

3 December 2017

1 reference